Related Experiment Video
Updated: Mar 21, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review
Christina Mangurian1,2,3, John W Newcomer4, Chelsea Modlin5
1Department of Psychiatry, University of California, San Francisco (UCSF), San Francisco, CA, USA. christina.mangurian@ucsf.edu.
Insights
Severe mental illness (SMI) patients face higher cardiovascular disease (CVD) risks, yet screening for conditions like diabetes remains critically low. Over 2 million adults with SMI likely have undiagnosed diabetes, leading to significant preventable costs and morbidity.
Area of Science:
- Medical Research
- Public Health
- Psychiatry
Background:
- Severe mental illness (SMI) affects nearly 19 million US adults, who experience a 25-year mortality gap, primarily due to cardiovascular disease (CVD).
- Antipsychotic medications, crucial for SMI treatment, elevate risks for obesity, type 2 diabetes, dyslipidemia, and hypertension, necessitating metabolic monitoring per ADA/APA guidelines.
Observation:
- Despite established guidelines, up to 70% of individuals on antipsychotics are not screened for diabetes and other CVD risk factors.
- An estimated 20% of US adults with SMI have diabetes, with over 2 million cases likely undiagnosed due to inadequate screening.
Findings:
- Suboptimal screening and treatment of diabetes and CVD risk factors are prevalent in the SMI population.
- Significant disparities in screening exist among SMI subpopulations, including racial/ethnic minorities, women, and children.
Implications:
- Failure to identify diabetes in SMI patients incurs over $8 billion annually in preventable healthcare costs.
- Clinical and policy interventions are urgently needed to improve CVD risk screening and management for this vulnerable population.
- Recommendations include optimizing antipsychotic treatment, enhancing smoking cessation, integrating care, and improving health record sharing.
Abstract:
Close to 19 million US adults have severe mental illnesses (SMI), and they die, on average, 25 years earlier than the general population, most often from cardiovascular disease (CVD). Many of the antipsychotic medications used to treat SMI contribute to CVD risk by increasing risk for obesity, type 2 diabetes, dyslipidemia, and hypertension. Based on compelling evidence, the American Diabetes Association and the American Psychiatric Association developed guidelines for metabolic screening and monitoring during use of these medications.In this manuscript, we have reviewed the evidence on diabetes and other CVD risk screening, prevalence, and management among populations with SMI. We also review differences in screening among subpopulations with SMI (e.g., racial/ethnic minorities, women, and children). We found that despite national guidelines for screening for diabetes and other cardiovascular risk factors, up to 70 % of people taking antipsychotics remain unscreened and untreated. Based on estimates that 20 % of the 19 million US adults with SMI have diabetes and 70 % of them are not screened; it is likely that over 2 million Americans with SMI have unidentified diabetes. Given that undiagnosed diabetes costs over $4,000 per person, this failure to identify diabetes among people with SMI represents a missed opportunity to prevent morbidity and translates to over $8 billion in annual preventable costs to our healthcare system.Given the high burden of disease and significant evidence of suboptimal medical care received by people with SMI, we propose several clinical and policy recommendations to improve diabetes and other CVD risk screening and care for this highly vulnerable population. These recommendations include reducing antipsychotic medication dose or switching antipsychotic medications, enhancing smoking cessation efforts, sharing electronic health records between physical and mental health care systems, and promoting integration of care.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Acute Coronary Syndrome IV: Interprofessional Care

